Yıl: 2020 Cilt: 3 Sayı: 2 Sayfa Aralığı: 167 - 172 Metin Dili: İngilizce DOI: 10.5505/anatoljfm.2020.41636 İndeks Tarihi: 06-06-2021

Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia

Öz:
Objectives: We aimed to evaluate the metabolic syndrome (MetS) parameters in patients with fibromyalgiasyndrome.Methods: Age, weight, height, body mass index, waist and hip circumferences, and blood pressure were recorded. Laboratory parameters included fasting blood glucose and insulin, high-density lipoprotein, and triglyceride, HOMA-IR.Results: Thirty-five female patients aged 20-64 years with fibromyalgia and 29 age-matched healthy controlswere included in this case-control study. Although MetS was more prevalent in fibromyalgia patients than thecontrol group, the difference did not reach a statistically significant level [7 (20.0%) vs. 5 (17.2%), p=0.770]. Theprevalence of high waist circumference was significantly higher in the fibromyalgia group than the controlgroup [23 (65.7%) vs. 6 (20.7%), p<0.001]. High blood pressure was also more prevalent in fibromyalgia group[10 (28.6%) vs. 1 (3.4%), p=0.009]. Insulin resistance and dyslipidemia prevalence did not show a significantdifference between groups (p=0.830 and p=0.250, respectively).Conclusion: Although statistically insignificant, metabolic prevalence increases in patients with fibromyalgia,while some MetS parameters, including waist circumference, and systolic and diastolic blood pressures, weresignificantly higher in fibromyalgia. Therefore, fibromyalgia patients may be under greater risk of MetS thanthe general population. For a definitive conclusion on the MetS and fibromyalgia, further large-scale studiesare needed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res [Hoboken] 2010;62:600– 10.
  • 2. Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Häuser W, Wolfe F. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol2011;38:2238–46.
  • 3. Busse JW, Ebrahim S, Connell G, Coomes EA, Bruno P, Malik K, et al. Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol. Syst Rev 2013;2:18.
  • 4. Hawkins RA. Fibromyalgia: a clinical update. J Am Osteopath Assoc2013;113:680–9.
  • 5. Ceko M, Bushnell MC, Gracely RH. Neurobiology underlying fibromyalgia symptoms. Pain Res Treat 2012;2012:585419.
  • 6. Fitzcharles MA, Ste-Marie PA, Pereira JX; Canadian Fibromyalgia Guidelines Committee. Fibromyalgia: evolving concepts over the past 2 decades. CMAJ 2013;185(13):E645–E51.
  • 7. Clauw DJ, Arnold LM, McCarberg BH; FibroCollaborative. The science of fibromyalgia. Mayo Clin Proc 2011;86:907–11.
  • 8. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007;36(6):339–56.
  • 9. Smith HS, Harris R, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 2011;14:E217–45.
  • 10. Russell IJ, Larson AA. Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheum Dis Clin North Am 2009;35(2):421–35.
  • 11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–97.
  • 12. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther2008;10:207.
  • 13. Bergmann N, Gyntelberg F, Faber J. The appraisal of chronic stress and the development of the metabolic syndrome: a systematic review of prospective cohort studies. Endocr Connect 2014;3:R55–80.
  • 14. Ferraz-Amaro I, González-Juanatey C, López-Mejias R, Riancho-Zarrabeitia L, González-Gay MA. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm2013;2013:710928.
  • 15. Assumpção A, Cavalcante AB, Capela CE, Sauer JF, Chalot SD, Pereira CA, et al. Prevalence of fibromyalgia in a low socioeconomic status population. BMC MusculoskeletDisord2009;10:64.
  • 16. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47(10):1643–9.
  • 17. Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol2003;30:369–78.
  • 18. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19–28.
  • 19. Lindell L, Bergman S, Petersson IF, Jacobsson LT, Herrström P. Prevalence of fibromyalgia and chronic widespread pain. Scand J Prim Health Care 2000;18:149–53.
  • 20. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.Arch Intern Med 2003;163(4):427–36.
  • 21. Onat A, Senocak M. Obesity in Turkish adults: prevalence, validity as a coronary risk factor and interrelation with other risk factors. Int J Ang 1995;4:94–8. 22. Gundogan K, Bayram F, Gedik V, Kaya A, Karaman A, Demir O, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci 2013;9:243–53.
  • 23. Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. RheumatolInt2011;31:1403–8.
  • 24. Kim CH, Luedtke CA, Vincent A, Thompson JM, Oh TH. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care Res (Hoboken) 2012;64(2):222–8.
  • 25. Yanmaz MN, Mert M, Korkmaz M. The prevalence of fibromyalgia syndrome in a group of patients with diabetes mellitus. RheumatolInt 2012;32(4):871–4.
  • 26. Tishler M, Smorodin T, Vazina-Amit M, Ramot Y, Koffler M, Fishel B. Fibromyalgia in diabetes mellitus. RheumatolInt 2003;23(4):171–3.
  • 27. Loevinger BL, Muller D, Alonso C, Coe CL. Metabolic syndrome in women with chronicpain. Metabolism 2007;56:87–93.
  • 28. Xiao Y, Haynes WL, Michalek JE, Russell IJ. Elevated serum high-sensitivity Creactiveprotein levels in fibromyalgia syndrome patients correlate with body mass index,interleukin-6, interleukin-8, erythrocyte sedimentation rate. RheumatolInt2013;33:1259–64.
  • 29. Cordero MD, Alcocer-Gómez E, Cano-García FJ, Sánchez-Domínguez B, FernándezRiejoP, Moreno Fernández AM, et al. Clinicalsymptoms in fibromyalgia are associated to overweight and lipid profile. RheumatolInt2014;34:419–22.
  • 30. Afsar B, Burucu R. Urinary albumin, protein excretion and circadian blood pressure inpatients with fibromyalgia. RheumatolInt2013;33:2391–8.
  • 31. Almodóvar R, Carmona L, Zarco P, Collantes E, González C, Mulero J, et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. ClinExpRheumatol 2010;28:S33–9.
  • 32. Azevedo VF, Paiva Edos S, Felippe LR, Moreira RA. Occurrence of fibromyalgia in patients with ankylosing spondylitis. [Article in English, Portuguese] Rev Bras Reumatol 2010;50(6):646– 50.
  • 33. Zammurrad S, Munir W, Farooqi A. Disease activity score in rheumatoid arthritis with or without secondary fibromyalgia. J Coll Physicians Surg Pak 2013;23:413–7.
APA Darçın T, KART KÖSEOĞLU H (2020). Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. , 167 - 172. 10.5505/anatoljfm.2020.41636
Chicago Darçın Tahir,KART KÖSEOĞLU HAMİDE Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. (2020): 167 - 172. 10.5505/anatoljfm.2020.41636
MLA Darçın Tahir,KART KÖSEOĞLU HAMİDE Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. , 2020, ss.167 - 172. 10.5505/anatoljfm.2020.41636
AMA Darçın T,KART KÖSEOĞLU H Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. . 2020; 167 - 172. 10.5505/anatoljfm.2020.41636
Vancouver Darçın T,KART KÖSEOĞLU H Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. . 2020; 167 - 172. 10.5505/anatoljfm.2020.41636
IEEE Darçın T,KART KÖSEOĞLU H "Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia." , ss.167 - 172, 2020. 10.5505/anatoljfm.2020.41636
ISNAD Darçın, Tahir - KART KÖSEOĞLU, HAMİDE. "Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia". (2020), 167-172. https://doi.org/10.5505/anatoljfm.2020.41636
APA Darçın T, KART KÖSEOĞLU H (2020). Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. The anatolian journal of family medicine (Online) , 3(2), 167 - 172. 10.5505/anatoljfm.2020.41636
Chicago Darçın Tahir,KART KÖSEOĞLU HAMİDE Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. The anatolian journal of family medicine (Online) 3, no.2 (2020): 167 - 172. 10.5505/anatoljfm.2020.41636
MLA Darçın Tahir,KART KÖSEOĞLU HAMİDE Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. The anatolian journal of family medicine (Online) , vol.3, no.2, 2020, ss.167 - 172. 10.5505/anatoljfm.2020.41636
AMA Darçın T,KART KÖSEOĞLU H Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. The anatolian journal of family medicine (Online) . 2020; 3(2): 167 - 172. 10.5505/anatoljfm.2020.41636
Vancouver Darçın T,KART KÖSEOĞLU H Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia. The anatolian journal of family medicine (Online) . 2020; 3(2): 167 - 172. 10.5505/anatoljfm.2020.41636
IEEE Darçın T,KART KÖSEOĞLU H "Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia." The anatolian journal of family medicine (Online) , 3, ss.167 - 172, 2020. 10.5505/anatoljfm.2020.41636
ISNAD Darçın, Tahir - KART KÖSEOĞLU, HAMİDE. "Evaluation of Metabolic Syndrome Prevalence and Parameters in Patients with Fibromyalgia". The anatolian journal of family medicine (Online) 3/2 (2020), 167-172. https://doi.org/10.5505/anatoljfm.2020.41636